Alimentary Pharmacology & Therapeutics

VOLUME 17 PAGES 1–1590 2003

Editors
R E Pounder and W L Peterson

Editorial Board

Chairman J-R Malagelada
R Arnold
A T R Axon
K D Bardhan
G Bianchi Porro
H G Dammann
G Delle Fave
B M Fennerty
R L Fisher
A G Fraser
N J Greenberger
E G Hahn
S B Hanauer
C J Hawkey
P Hayes
R V Heatley
H J F Hodgson
G J Holtmann
C W Howden
R Hunt
D P Jewell
K Kawai
K Kimura
G J Krejs
S K Lam
R Lambert
C B H W Lamers
M J S Langman
D A Lieberman
P Malfertheiner
D C Metz
M Mignon
S Okabe
C O'Morain
D S Rampton
J Rask-Madsen
J M Rhodes
J Rodes
P Rutgeerts
P Schoenfeld
F Shanahan
R A Smallwood
A Sonnenberg
R Spiller
V Stanghellini
R W Stockbrugger
J J Y Sung
N J Talley
A Terano
W J Tremaine
G N Tytgat
N Vakil
J L Wallace
R P Walt
M Wolfe
S-D Xiao

Blackwell
Publishing

© 2003 Blackwell Publishing
Published by Blackwell Publishing Ltd
23 Ainslie Place, Edinburgh EH3 6AJ

Other Editorial Offices:
Blackwell Publishing Inc., Commerce Place, 350 Main Street, Malden, MA 02148-5018, USA
Blackwell Publishing Asia, 54 University Street, Carlton South, Victoria 3053, Australia
Blackwell Publishing KK, MG Kodenmacho Bldg, 7–10 Kodenmacho Nihombashi, Chuo-ku, Tokyo 104, Japan
Blackwell Publishing France, 10 rve Casimir Delavigne, 75006 Paris, France

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01973, USA. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to the Editor, *Alimentary Pharmacology & Therapeutics*. ISSN 0269–2813/03 $15.00

Alimentary Pharmacology & Therapeutics is included in the major information retrieval systems, including Index Medicus and Medline, the CINAHL index, CABS Science Citation Index, Current Contents—Life Sciences, Excerpta Medica and Current Opinion in Gastroenterology

ISSN 0269–2813
Typeset by SPS, Chennai, India:
Printed and bound by Bell & Bain, Glasgow, UK

Contents

VOLUME 17 NUMBER 1 1ST JANUARY

1 Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. *J. Medina, L. García-Buey & R. Moreno-Otero*

17 Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? *J. P. Gisbert, E. A. Jones, J. M. Pajares & R. Moreno-Otero*

29 Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. *W. J. Sandborn & S. B. Hanauer*

43 Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome — influence on psychiatric and gastrointestinal symptoms. *T. O. C. Kilkens, A. Honig, N. Rozendaal, M. A. Van Nieuwenhoven & R.-J. M. Brummer*

53 Systematic review: terlipressin in acute oesophageal variceal haemorrhage. *G. N. Ioannou, J. Doust & D. C. Rockey*

65 Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. *L. O. Reuther, J. Sonne, N. Larsen, J. F. Dahlerup, O. O. Thomsen & K. Schmiegelow*

69 Mercaptopurine metabolite results in clinical gastroenterology practice. *R. S. Bloomfeld & J. E. Onken*

75 Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. *W. V. Crandall & L. M. Mackner*

85 Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. *P. D. P. Lundin, S. Edsbäcker, M. Bergstrand, J. Ejderhamn, H. Linander, L. Högberg, T. Persson, J. C. Escher & B. Lindquist*

93 Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. *G. Aumais, M. Lefebvre, C. Tremblay, A. Bitton, F. Martin, A. Giard, M. Madi & J. Spénard*

99 Risk factors for failure of *Helicobacter pylori* therapy — results of an individual data analysis of 2751 patients. *N. Broutet, S. Tchamgoué, E. Pereira, H. Lamouliatte, R. Salamon & F. Mégraud*

111 Is eradication sufficient to heal gastric ulcers in patients infected with *Helicobacter pylori*? A randomized, controlled, prospective study. *K. Higuchi, Y. Fujiwara, K. Tominaga, T. Watanabe, M. Shiba, S. Nakamura, N. Oshitani, T. Matsumoto & T. Arakawa*

119 Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line *Helicobacter pylori* eradication in Japan, and the influence of metronidazole resistance. *K. Murakami, R. Sato, T. Okimoto, M. Nasu, T. Fujioka, M. Kodama & J. Kagawa*

125 Human recombinant lactoferrin is ineffective in the treatment of human *Helicobacter pylori* infection. *Y. Guttner, H. M. Windsor, C. H. Viiala & B. J. Marshall*

131 Once-daily, low-cost, highly effective *Helicobacter pylori* treatment to family members of gastric cancer patients. *L. G. V. Coelho, G. M. Martins, M. C. F. Passos, M. L. Bueno, B. S. F. Sanches, L. G. Lopes, C. H. D. Miranda & L. P. Castro*

137 Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. *M. I. Prince, H. C. Mitchison, D. Ashley, D. A. Burke, N. Edwards, M. G. Bramble, O. F. W. James & D. E. J. Jones*

145 Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. *B. L. Hicken, A. I. Sharara, G. A. Abrams, M. Eloubeidi, M. B. Fallon & M. R. Arguedas*

155 Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. *D. C. Metz, W. J. Bochenek & The Pantoprazole US GERD Study Group*

165 Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. *S. Chaussade & M. Minić*

173 Letter to the Editors. *L. Filik, A. Ulker, U. Dagli, E. Parlak, B. Tunc & S. Disibeyaz*

VOLUME 17 NUMBER 2 15TH JANUARY

175 Review article: psychiatry, psychotherapy and gastroenterology — bringing it all together. *J. M. Stern*

185 Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. *P. Rutgeerts, L. Lemmens, G. Van Assche, M. Noman, I. Borghini-Fuhrer & R. Goedkoop*

193 Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. *D. Y. Graham, A. R. Opekun, Y. Yamaoka, M. S. Osato & H. M. T. El-Zimaity*

201 Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. *R. H. Hunt, S. Harper, P. Callegari, C. Yu, H. Quan, J. Evans, C. James, B. Bowen & F. Rashid*

211 Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. *M. J. Kaviani, M. R. Hashemi, A. R. Kazemifar, S. Roozitalab, A.-A. Mostaghni, S. Merat, M. Alizadeh-Naini & H. Yarmohammadi*

217 Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia. *J.-C. Luo, H.-Y. Lin, F.-Y. Chang, R.-H. Lu, C.-L. Lu, C.-Y. Chen & S.-D. Lee*

225 Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. *R. A. Enns, Y. M. Gagnon, K. P. Rioux & A. R. Levy*

235 Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. *M. Frazzoni, E. De Micheli, A. Grisendi & V. Savarino*

243 Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. *M. F. Vela, R. Tutuian, P. O. Katz & D. O. Castell*

253 A rapid-release 50-mg tablet-based ^{13}C-urea breath test for the diagnosis of *Helicobacter pylori* infection. *W. M. Wong, S. K. Lam, K. C. Lai, K. M. Chu, H. H. X. Xia, K. W. Wong, K. L. Cheung, S. K. Lin & B. C. Y. Wong*

259 Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of *Helicobacter pylori* infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. *H. Kawabata, Y. Habu, H. Tomioka, H. Kutsumi, M. Kobayashi, K. Oyasu, T. Hayakumo, S. Mizuno, K. Kiyota, M. Nakajima, K. Kimoto, H. Inokuchi & K. Kawai*

265 Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. *L. Favennec, J. Jave Ortiz, G. Gargala, N. Lopez Chegne, A. Ayoub & J. F. Rossignol*

271 Study of liver function in healthy elderly subjects using the ^{13}C-methacetin breath test. *R. Ciccocioppo, M. Candelli, D. Di Francesco, F. Ciocca, G. Taglieri, A. Armuzzi, G. Gasbarrini & A. Gasbarrini*

279 Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT$_3$ receptors. *M. Simrén, L. Simms, D. D'Souza, H. Abrahamsson & E. S. Björnsson*

289 Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. *C.-K. Hui, K.-C. Lai, M. Ng, W.-M. Wong, M.-F. Yuen, S.-K. Lam, C.-L. Lai & B. C. Y. Wong*

VOLUME 17 NUMBER 3 1ST FEBRUARY

297 Review article: *Helicobacter pylori* and reflux disease. *P. Sharma & N. Vakil*

307 Review article: nutrition and adult inflammatory bowel disease. *J. Goh & C. A. O'Morain*

321 Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. *R. Micklewright, S. Lane, W. Linley, C. McQuade, F. Thompson & N. Maskrey*

333 Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. *K. Lauritsen, J. Devière, M.-A. Bigard, E. Bayerdörffer, G. Mózsik, F. Murray, S. Kristjánsdóttir, V. Savarino, K. Vetvik, D. De Freitas, V. Orive, L. Rodrigo, M. Fried, J. Morris, H. Schneider, S. Eklund & A. Larkö*

343 A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. *B. Thjodleifsson, G. Rindi, R. Fiocca, T. J. Humphries, A. Morocutti, N. Miller & K. D. Bardhan (for the European Rabeprazole Study Group)*

353 Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD). *P. Zentilin, P. Dulbecco, C. Bilardi, C. Gambaro, E. Iiritano, R. Biagini, G. S. Mela, L. Tessieri, M. R. Mele, C. Mansi, N. Pandolfo, S. Vigneri & V. Savarino*

361 Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. *J. W. Freston, Y.-L. Chiu, D. J. Mulford & E. D. Ballard II*

369 Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. *H. H. X. Xia, K. C. Lai, S. K. Lam, W. H. C. Hu, N. Y. H. Wong, W. M. Hui, C. P. Lau, W. H. Chen, C. K. Chan, W. M. Wong & B. C. Y. Wong*

379 Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. *E. Cheong, L. Igali, I. Harvey, M. Mole, E. Lund, I. T. Johnson & M. Rhodes*

387 Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. *S. J. Bell, S. Halligan, A. C. J. Windsor, A. B. Williams, P. Wiesel & M. A. Kamm*

395 Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. *M. Brunner, R. Assandri, K. Kletter, M. Tschurlovits, M. E. Corrado, R. Villa, H. G. Eichler & M. Müller*

403 Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole. *S. Edsbäcker, P. Larsson & M. Bergstrand*

409 Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. *T. Andus, F. Klebl, G. Rogler, N. Bregenzer, J. Schölmerich & R. H. Straub*

415 Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of *Helicobacter pylori*: an international multicentre study. *C. O'Morain, T. Borody, A. Farley, W. A. De Boer, C. Dallaire, R. Schuman, J. Piotrowski, C. A. Fallone, G. Tytgat, F. Mégraud & J. Spénard*

421 *Helicobacter pylori* strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. *F. Russo, P. Berloco, R. Cuomo, M. L. Caruso, G. Di Matteo, P. Giorgio, V. De Francesco, A. Di Leo & E. Ierardi*

429 Effect of frequent consumption of a *Lactobacillus casei*-containing milk drink in *Helicobacter pylori*-colonized subjects. *A. Cats, E. J. Kuipers, M. A. R. Bosschaert, R. G. J. Pot, C. M. J. E. Vandenbroucke-Grauls & J. G. Kusters*

437 Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. *J. Garland, J. R. Buscombe, C. Bouvier, P. Bouloux, M. H. Chapman, A. C. Chow, N. Reynolds & M. E. Caplin*

445 Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. *K. J. Goerg & Th. Spilker*

453 *Helicobacter* DNA in bile: correlation with hepato-biliary diseases. *C. A. Fallone, S. Tran, M. Semret, F. Discepola, M. Behr & A. N. Barkun*

459 Oral desensitizing treatment in food allergy: clinical and immunological results. *G. Patriarca, E. Nucera, C. Roncallo, E. Pollastrini, F. Bartolozzi, T. De Pasquale, A. Buonomo, G. Gasbarrini, C. Di Campli & D. Schiavino*

467 A prospective, comparative study of the para-aminobenzoic acid test and faecal elastase 1 in the assessment of exocrine pancreatic function. *S. A. Sonwalkar, I. B. Holbrook, I. Phillips & S. M. Kelly*

473 Second harmonic imaging improves trans-abdominal ultrasound detection of biliary sludge in 'idiopathic' pancreatitis. *E. Ierardi, N. Muscatiello, M. Nacchiero, M. Gentile, M. Margiotta, S. Marangi, V. De Francesco, R. Francavilla, M. Barone, D. Faleo, C. Panella, A. Francavilla & R. Cuomo*

479 Letter to the Editors. *J. T. Siveke & C. Folwaczny*

VOLUME 17 NUMBER 4 15TH FEBRUARY

481 Review article: esomeprazole — enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. *P. Lindberg, D. Keeling, J. Fryklund, T. Andersson, P. Lundborg & E. Carlsson*

489 Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. *S. Alsalameh, M. Burian, G. Mahr, B. G. Woodcock & G. Geisslinger*

503 6-Thioguanine — efficacy and safety in chronic active Crohn's disease. *K. R. Herrlinger, W. Kreisel, M. Schwab, J. Schoelmerich, W. E. Fleig, A. Ruhl, M. Reinshagen, K. Fellermann, R. Greinwald & E. F. Stange*

509 Effect of *Lactobacillus rhamnosus* GG on ileal pouch inflammation and microbial flora. *J. Kuisma, S. Mentula, H. Jarvinen, A. Kahri, M. Saxelin & M. Farkkila*

517 Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. *R. Caprilli, M. Cottone, F. Tonelli, G. Sturniolo, F. Castiglione, V. Annese, C. Papi, A. Viscido, C. Cammà, G. Corrao & G. Latella*

525 A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. *S. Edsbäcker, B. Bengtsson, P. Larsson, P. Lundin, Å. Nilsson, J. Ulmius & P. Wollmer*

537 Non-erosive reflux disease (NERD) — acid reflux and symptom patterns. *S. D. Martinez, I. B. Malagon, H. S. Garewal, H. Cui & R. Fass*

547 Reflux and Barrett's oesophagus after gastric surgery — long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis. *A. S. Taha, W. J. Angerson & C. G. Morran*

553 Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for *Helicobacter pylori* infection. *W. M. Wong, Q. Gu, S. K. Lam, F. M. Y. Fung, K. C. Lai, W. H. C. Hu, Y. K. Yee, C. K. Chan, H. H. X. Xia, M. F. Yuen & B. C. Y. Wong*

561 Gallstones — an increasing problem: a study of hospital admissions in England between 1989/1990 and 1999/2000. *J.-Y. Kang, C. Ellis, A. Majeed, J. Hoare, A. Tinto, R. C. N. Williamson, C. J. Tibbs & J. D. Maxwell*

571 Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. *A. Dick, S. Keady, F. Mohamed, S. Brayley, M. Thomson, B. W. Lloyd, R. Heuschkel & N. A. Afzal*

577 Tegaserod, a 5-HT_4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. *B. Coffin, J.-P. Farmachidi, P. Rueegg, A. Bastie & D. Bouhassira*

587 Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study. *M. Peräaho, K. Kaukinen, K. Paasikivi, H. Sievänen, S. Lohiniemi, M. Mäki & P. Collin*

595 Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. *F. Esposito, F. Morisco, V. Verde, A. Ritieni, A. Alezio, N. Caporaso & V. Fogliano*

603 Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. *J. Tack, D. Broekaert, B. Coulie, B. Fischler & J. Janssens*

609 Letter to the Editors. *G. K. Isbister, F. Downes & I. M. Whyte*

VOLUME 17 NUMBER 5 1ST MARCH

611 Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis. *C. S. S. Lee*
623 Review article: visceral hypersensitivity. *H. Mertz*
635 Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. *R. Lea, L. A. Houghton, E. L. Calvert, S. Larder, W. M. Gonsalkorale, V. Whelan, J. Randles, P. Cooper, P. Cruickshanks, V. Miller & P. J. Whorwell*
643 The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. *A. P. S. Hungin, P. J. Whorwell, J. Tack & F. Mearin*
651 General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. *L. M. Gladman & D. A. Gorard*
655 Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971–1998/1999. *A. Newnham, M. J. Quinn, P. Babb, J. Y. Kang & A. Majeed*
665 Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971–1998. *A. Newnham, M. J. Quinn, P. Babb, J. Y. Kang & A. Majeed*
677 Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. *Z. H. Khan, E. J. Simpson, A. T. Cole, M. Holt, I. MacDonald, D. Pye, A. Austin & J. G. Freeman*
683 The prophylactic use of a proton pump inhibitor before food and alcohol. *C. O'Leary, J. McCarthy, M. Humphries, F. Shanahan & E. Quigley*
687 A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. *M. Buti, M. Medina, M. A. Casado, J. B. Wong, L. Fosbrook & R. Esteban*
695 Role of immunosuppression in the development of quinolone-resistant *Escherichia coli* spontaneous bacterial peritonitis and in the mortality of *E. coli* spontaneous bacterial peritonitis. *F. Cereto, I. Molina, A. González, O. Del Valle, R. Esteban, J. Guardia & J. Genescà*
703 Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. *J. Agnholt, J. F. Dahlerup, S. Buntzen, A. Tøttrup, S. Lyhne Nielsen & E. Lundorf*
711 Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. *R. W. L. Leong, Y. T. Lee, J. Y. L. Ching & J. J. Y. Sung*
719 High eradication rates of *Helicobacter pylori* with a new sequential treatment. *A. Zullo, D. Vaira, N. Vakil, C. Hassan, L. Gatta, C. Ricci, V. De Francesco, M. Menegatti, A. Tampieri, F. Perna, V. Rinaldi, F. Perri, C. Papadia, F. Fornari, S. Pilati, L. S. Mete, A. Merla, R. Potì, G. Marinone, A. Savioli, S. M. A. Campo, D. Faleo, E. Ierardi, M. Miglioli & S. Morini*
727 Stool antigen for the diagnosis of *Helicobacter pylori* infection in cirrhosis: comparative usefulness of three different methods. *X. Calvet, M. Quesada, M. Roselló, F. Salceda, I. Sanfeliu, B. Dalmau & M. Gil*

VOLUME 17 NUMBER 6 15TH MARCH

733 Review article: pancreatic function testing. *R. S. Chowdhury & C. E. Forsmark*

751 Systematic review: rabeprazole-based therapies in *Helicobacter pylori* eradication. *J. P. Gisbert, S. Khorrami, X. Calvet & J. M. Pajares*

765 Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. *R. San Miguel, J. Mar, J. M. Cabasés, F. Guillén-Grima & M. Buti*

775 Eradication of *Helicobacter pylori* increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. *M. P. Williams, B. Usselmann, A. Chilton, J. Sercombe, C. U. Nwokolo & R. E. Pounder*

785 Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis. *J. H. S. You, A. C. M. Lee, S. C. Y. Wong & F. K. L. Chan*

793 A rapid, low-dose, ^{13}C-urea tablet for the detection of *Helicobacter pylori* infection before and after treatment. *L. Gatta, N. Vakil, C. Ricci, J. F. Osborn, A. Tampieri, F. Perna, M. Miglioli & D. Vaira*

799 Effect of treatment of *Helicobacter pylori* on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. *K. C. Lai, C. S. Lau, W. Y. Ip, B. C. Y. Wong, W. M. Hui, W. H. C. Hu, R. W. M. Wong & S. K. Lam*

807 Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. *C. Von Tirpitz, J. Klaus, M. Steinkamp, L. C. Hofbauer, W. Kratzer, R. Mason, B. O. Boehm, G. Adler & M. Reinshagen*

817 Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case–control study. *M. H. Gleeson & A. J. M. Davis*

827 Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. *B. Nørgård, L. Pedersen, K. Fonager, S. N. Rasmussen & H. T. Sørensen*

835 Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia. *A. Quadri & N. Vakil*

841 Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. *N. A. Koloski, N. J. Talley, S. S. Huskic & P. M. Boyce*

853 Longevity of silicone and polyurethane catheters in long-term enteral feeding via percutaneous endoscopic gastrostomy. *S. Sartori, L. Trevisani, I. Nielsen, D. Tassinari, P. Ceccotti & V. Abbasciano*

VOLUME 17 NUMBER 7 1ST APRIL

857 Review article: pruritus in cholestatic and other liver diseases. *M. Mela, A. Mancuso & A. K. Burroughs*

871 Therapeutic value of a gastroenterology consultation in irritable bowel syndrome. *A. Ilnyckyj, L. A. Graff, J. F. Blanchard & C. N. Bernstein*

881 The impact of gastrointestinal symptoms on health status in patients with cardiovascular disease. *R. J. F. Laheij, L. G. M. Van Rossum, P. F. M. Krabbe, J. B. M. J. Jansen & F. W. A. Verheugt*

887 Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. *R. J. Lancashire, K. Cheng & M. J. S. Langman*

895 A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. *H. J. Kim, M. Camilleri, S. Mckinzie, M. B. Lempke, D. D. Burton, G. M. Thomforde & A. R. Zinsmeister*

905 Antibiotic-associated diarrhoea and *Clostridium difficile* in the community. *L. Beaugerie, A. Flahault, F. Barbut, P. Atlan, V. Lalande, P. Cousin, M. Cadilhac & J.-C. Petit (for the study group)*

913 High-dose azathioprine in children with inflammatory bowel disease. *D. Fuentes, F. Torrente, S. Keady, K. Thirrupathy, M. A. Thomson, J. A. Walker-Smith, S. H. Murch & R. B. Heuschkel*

923 Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. *S. P. Pereira, I. M. Bain, D. Kumar & R. H. Dowling*

935 Clinical and pathological implications of IgG antibody responses to *Helicobacter pylori* and its virulence factors in non-ulcer dyspepsia. *H. H.-X. Xia, N. J. Talley, A. L. Blum, C. A. O'Morain, M. Stolte, E. Bolling-Sternevald & H. M. Mitchell*

945 Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. *J. D. Gardner, S. Sloan, P. B. Miner Jr & M. Robinson*

955 Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. *J. D. Gardner, S. Sloan, P. B. Miner Jr & M. Robinson*

965 The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. *M. Kawamura, S. Ohara, T. Koike, K. Iijima, J. Suzuki, S. Kayaba, K. Noguchi, S. Hamada, M. Noguchi & T. Shimosegawa*

975 Letter to the Editors. *B. May, P. Funk & B. Schneider*

VOLUME 17 NUMBER 8 15TH APRIL

977 Review article: non-alcoholic fatty liver disease. *L. M. Alba & K. Lindor*

987 Review article: the diagnosis of coeliac disease. *A. S. Abdulkarim & J. A. Murray*

997 Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. *W. L. Hasler & P. Schoenfeld*

1007 Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat. *A. Ullrich, J. Erdmann, J. Margraf & V. Schusdziarra*

1015 A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. *J. Labenz, K. U. Petersen, W. Rösch & H. R. Koelz*

1021 Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. *U. Ladabaum*

1031 Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. *C. Hézode, I. Lonjon, F. Roudot-Thoraval, J.-M. Pawlotsky, E.-S. Zafrani & D. Dhumeaux*

1039 The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. *M. Sans, D. Tàssies, M. Pellisé, G. Espinosa, L. Quintó, J. M. Piqué, J. C. Reverter & J. Panés*

1049 Reflux symptoms in general practice: diagnostic evaluation of the Carlsson–Dent gastro-oesophageal reflux disease questionnaire. *M. E. Numans & N. J. De Wit*

1057 *Helicobacter pylori* infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. *P. Zentilin, E. Iiritano, C. Vignale, C. Bilardi, M. R. Mele, P. Spaggiari, C. Gambaro, P. Dulbecco, L. Tessieri, S. Reglioni, C. Mansi, L. Mastracci, S. Vigneri, R. Fiocca & V. Savarino*

1065 Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of *Helicobacter pylori* in patients with documented peptic ulcer disease. *C. J. Hawkey, J. C. Atherton, H. C. Treichel, B. Thjodleifsson & M. Ravic*

1075 Antigen stool test for assessment of *Helicobacter pylori* infection in patients with upper gastrointestinal bleeding. *U. Peitz, A. Leodolter, S. Kahl, K. Agha-Amiri, T. Wex, K. Wolle, T. Günther, B. Steinbrink & P. Malfertheiner*

VOLUME 17 NUMBER 9 1ST MAY

1085 Review article: the advent of capsule endoscopy — a not-so-futuristic approach to obscure gastrointestinal bleeding. *B. Lewis & N. Goldfarb*

1097 Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. *S. R. Orenstein, T. M. Shalaby, S. N. Devandry, C. A. Liacouras, S. J. Czinn, J. E. Dice, T. J. Simon, S. P. Ahrens & L. A. Stauffer*

1109 Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in *Helicobacter pylori*-negative subjects. *G. V. Ohning, J. H. Walsh, J. R. Pisegna, A. Murthy, J. Barth & T. O. G. Kovacs*

1115 Non-cardiac chest pain: prevalence, risk factors, impact and consulting — a population-based study. *G. D. Eslick, M. P. Jones & N. J. Talley*

1125 *Helicobacter pylori* eradication and gastric ulcer healing — comparison of three pantoprazole-based triple therapies. *P. Malfertheiner, T. Kirchner, M. Kist, A. Leodolter, U. Peitz, S. Strobel, M. Bohuschke, G. Gatz & The BYK Advanced Gastric Ulcer Study (BAGUS) Group*

1137 Triple vs. quadruple therapy for treating *Helicobacter pylori* infection: a meta-analysis. *E. Gené, X. Calvet, R. Azagra & J. P. Gisbert*

1145 The clinical course of fistulating Crohn's disease. *S. J. Bell, A. B. Williams, P. Wiesel, K. Wilkinson, R. C. G. Cohen & M. A. Kamm*

1153 Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. *I. R. Wilding, C. Behrens, S. J. Tardif, H. Wray, P. Bias & W. Albrecht*

1163 Gastrointestinal transit and release of 5-aminosalicylic acid from ^{153}Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. *M. Brunner, R. Greinwald, K. Kletter, H. Kvaternik, M. E. Corrado, H. G. Eichler & M. Müller*

1171 Diagnostic investigation rates and use of prescription and non-prescription medications amongst dyspeptics: a population-based study of 2300 Australians. *J. I. Westbrook & N. J. Talley*

1179 Development and validation of the Diabetes Bowel Symptom Questionnaire. *C. Quan, N. J. Talley, S. Cross, M. Jones, J. Hammer, N. Giles & M. Horowitz*

1189 Diverticular disease of the colon — on the rise: a study of hospital admissions in England between 1989/1990 and 1999/2000. *J. Y. Kang, J. Hoare, A. Tinto, S. Subramanian, C. Ellis, A. Majeed, D. Melville & J. D. Maxwell*

1197 Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone. *W. Sievert, R. Batey, L. Mollison, S. Pianko, J. McDonald, G. Marinos, W. Reed, S. Warner, S. Bowden, R. De Solom & P. Bhathal (for the AusHep investigators)*

1205 Errata

VOLUME 17 NUMBER 10 15TH MAY

1207 Review article: oral, modified-release mesalazine formulations — proprietary versus generic. *A. Forbes, A. Cartwright, S. Marchant, P. McIntyre & M. Newton*

1215 Systematic review: antacids, H_2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. *P. Moayyedi, S. Soo, J. Deeks, D. Forman, A. Harris, M. Innes & B. Delaney*

1229 Meta-analysis: proton pump inhibitor or H_2-receptor antagonist for *Helicobacter pylori* eradication. *D. Y. Graham, F. Hammoud, H. M. T. El-Zimaity, J. G. Kim, M.S. Osato & H. B. El-Serag*

1237 Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. *R. M. Klok, M. J. Postma, B. A. Van Hout & J. R. B. J. Brouwers*

1247 Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. *P. Mathurin, B. Raynard, S. Dharancy, S. Kirzin, D. Fallik, F.-R. Pruvot, V. Canva, J.-C. Paris, J.-C. Chaput & S. Naveau*

1263 Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. *A. Viscido, F. I. Habib, A. Kohn, C. Papi, A. Marcheggiano, M. T. Pimpo, P. Vernia, G. Cadau & R. Caprilli*

1273 Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. *D. C. Baumgart, B. Wiedenmann & A. U. Dignass*

1283 The selection of triple therapy for *Helicobacter pylori* eradication in chronic renal insufficiency. *B.-S. Sheu, J.-J. Huang, H.-B. Yang, A.-H. Huang & J.-J. Wu*

1291 An inter- and intra-laboratory comparison of breath $^{13}CO_2$ analysis. *F. Perri, R. M. Zagari, J. S. Uebersax, M. Quitadamo, F. Bazzoli & The Helicobacter Pylori SIGE Study Group on $^{13}CO_2$ Measurement Standardization*

1299 Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy. *M. Pellisé, A. Castells, A. Ginès, M. Solé, J. Mora, S. Castellví-Bel, F. Rodríguez-Moranta, G. Fernàndez-Esparrach, J. Llach, J. M. Bordas, S. Navarro & J. M. Piqué*

1309 The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. *B. B. Dean, J.A. Crawley, C. M. Schmitt, J. Wong & J. J. Ofman*

1319 Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. *A. Mandal, R. J. Playford & A. C. Wicks*

1325 Refeeding syndrome: effective and safe treatment with Phosphates Polyfusor. *A. Terlevich, S. D. Hearing, W. W. Woltersdorf, C. Smyth, D. Reid, E. McCullagh, A. Day & C. S. J. Probert*

1331 Erratum

VOLUME 17 NUMBER 11 1ST JUNE

1333 Review article: the treatment of refractory *Helicobacter pylori* infection. *F. Mégraud & H. Lamouliatte*

1345 Review article: clinic-based testing for *Helicobacter pylori* infection by enzyme immunoassay of faeces, urine and saliva. *S. Kabir*

1355 Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *W. J. Sandborn, B. E. Sands, D. C. Wolf, J. F. Valentine, M. Safdi, S. Katz, K. L. Isaacs, L. D. Wruble, J. Katz, D. H. Present, E. V. Loftus Jr., F. Graeme-Cook, D. J. Odenheimer & S. B. Hanauer*

1365 Mycophenolate mofetil in refractory inflammatory bowel disease. *A. C. Ford, R. J. Towler, P. Moayyedi, D. M. Chalmers & A. T. R. Axon*

1371 An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. *W. Reinisch, W. Miehsler, C. Dejaco, M. Harrer, T. Waldhoer, C. Lichtenberger & H. Vogelsang*

1381 One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of *Helicobacter pylori* infection. *S. Veldhuyzen van Zanten, S. Machado & J. Lee*

1389 Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points. *J. S. Kalantar, G. R. Locke III, N. J. Talley, A. R. Zinsmeister, S. L. Fett & L. J. Melton III*

1399 Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. *A. Pilotto, G. Leandro & M. Franceschi (on behalf of the Ageing, Acid-Related Disease Study Group)*

1407 A validated symptoms questionnaire (Chinese GERDQ) for the diagnosis of gastro-oesophageal reflux disease in the Chinese population. *W. M. Wong, K. F. Lam, K. C. Lai, W. M. Hui, W. H. C. Hu, C. L. K. Lam, N. Y. H. Wong, H. H. X. Xia, J. Q. Huang, A. O. O. Chan, S. K. Lam & B. C. Y. Wong*

1415 Antibodies to human recombinant tissue transglutaminase may detect coeliac disease patients undiagnosed by endomysial antibodies. *N. Tesei, E. Sugai, H. Vázquez, E. Smecuol, S. Nivelom, R. Mazure, M. L. Moreno, J. C. Gomez, E. Mauriño & J. C. Bai*

1425 Letter to the Editors. *M. Z. D. Castle, D. B. A. Silk & G. W. Libby*

VOLUME 17 NUMBER 12 15TH JUNE

1427 Review article: endoscopic treatments for gastro-oesophageal reflux disease. *N. Vakil & P. Sharma*

1435 Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition. *P. Rutgeerts, S. Van Deventer & S. Schreiber*

1451 An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. *I. D. R. Arnott, G. McNeill & J. Satsangi*

1459 Remission maintenance by tioguanine in chronic active Crohn's disease. *K. R. Herrlinger, P. Deibert, M. Schwab, W. Kreisel, C. Fischer, K. Fellermann & E. F. Stange*

1465 NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. *R. W. L. Leong, A. Armuzzi, T. Ahmad, M. l. Wong, P. Tse, D. P. Jewell & J. J. Y. Sung*

1471 Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. *M. Campieri, S. Adamo, D. Valpiani, A. D'Arienzo, G. D'Albasio, M. Pitzalis, P. Cesari, T. Casetti, G. N. Castiglione, F. Rizzello, F. Manguso, G. Varoli & P. Gionchetti*

1481 The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study. *A. B. R. Thomson, A. N. Barkun, D. Armstrong, Naoki Chiba, R. J. White, S. Daniels, S. Escobedo, B. Chakraborty, P. Sinclair & S. J. O. Veldhuyzen Van Zanten*

1493 Conscious sedation with propofol in elderly patients: a prospective evaluation. *L. T. Heuss, P. Schnieper, J. Drewe, E. Pflimlin & C. Beglinger*

1503 Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. *F. Parente, C. Cucino, S. Gallus, S. Bargiggia, S. Greco, L. Pastore & G. Bianchi Porro*

1507 Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. *D. Pantoflickova, G. Dorta, M. Ravic, P. Jornod & A. L. Blum*

1515 Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. *D. Jaspersen, M. Kulig, J. Labenz, A. Leodolter, T. Lind, W. Meyer-Sabellek, M. Vieth, S. N. Willich, D. Lindner, M. Stolte & P. Malfertheiner*

1521 *CYP2C19* pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. *L. J. Egan, G. M. Myhre, D. C. Mays, R. A. Dierkhising, P. P. Kammer & J. A. Murray*

1529 Long-term observation of reflux oesophagitis developing after *Helicobacter pylori* eradication therapy. *A. Sasaki, K. Haruma, N. Manabe, S. Tanaka, M. Yoshihara & K. Chayama*

1535 Effect of cyclooxygenase-2 inhibition on human *Helicobacter pylori* gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention. *J. M. Scheiman, J. K. Greenson, J. Lee & B. Cryer*

1545 Is antimicrobial susceptibility testing necessary before second-line treatment for *Helicobacter pylori* infection? *H. Miwa, A. Nagahara, A. Kurosawa, T. Ohkusa, R. Ohkura, M. Hojo, N. Enomoto & N. Sato*

1553 The efficacy of omeprazole twice daily with supplemental H_2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. *W. C. Orr & M. J. Harnish*

1559 ^{13}C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin content and oxygen supply. *A. Zipprich, F. Meiss, N. Steudel, U. Sziegoleit, W. E. Fleig & G. Kleber*

1563 Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. *R. Testa, E. Testa, E. Giannini, F. Botta, F. Malfatti, B. Chiarbonello, A. Fumagalli, S. Polegato, E. Podesta, P. Romagnoli, D. Risso, G. Cittadini & G. D. E. Caro*